Alzheimer's disease (AD) is the most common cause of dementia worldwide, and its
prevalence is rapidly increasing due to extended lifespans. Among the increasing number of …

It has been 15 years since the advent of the genome-wide association study (GWAS) era.
Here, we review how this experimental design has realized its promise by facilitating an …

APOE4 is the strongest genetic risk factor for Alzheimer's disease,–. However, the effects of
APOE4 on the human brain are not fully understood, limiting opportunities to develop …

Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated
protein 9 (Cas9) gene-editing technology is the ideal tool of the future for treating diseases …

Studies in neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease
and Amyotrophic lateral sclerosis, Huntington's disease, and so on, have suggested that …

The impact of apolipoprotein E ε4 (APOE4), the strongest genetic risk factor for Alzheimer's
disease (AD), on human brain cellular function remains unclear. Here, we investigated the …

Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …

Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

Despite advances in uncovering the mechanisms that underlie neuroinflammation and
neurodegenerative disease, therapies that prevent neuronal loss remain elusive. Targeting …

Organoids are three-dimensional (3D) miniature structures cultured in vitro produced from
either human pluripotent stem cells (hPSCs) or adult stem cells (AdSCs) derived from …